Stéphane Champiat, MD, PhD, Talks Benefits With and Next Steps for SOT101 and Pembrolizumab

Video

Stéphane Champiat, MD, PhD, spoke about the reasoning behind using the IL-2/IL-15 superagonist SOT101 and where the research is heading for patients with solid tumors.

During the American Association for Cancer Research (AACR) 2022 Annual Meeting, CancerNetwork® spoke with Stéphane Champiat, MD, PhD, assistant professor at the Drug Development Department of Gustave Roussy Cancer Campus in Paris, France, about the phase 2 AURELIO-3 trial (NCT04542057), which examined SOT101, an interleukin (IL)–2/IL-15 superagonist, in combination with pembrolizumab (Keytruda). Patients with solid tumors who were treated with the combination experienced acceptable safety outcomes and highly promising efficacy signals. Champiat also mention the AURELIO-04 study (NCT05256381) which is underway to test SOT101 plus pembrolizumab in solid tumors.

Transcript:

IL [interleukin]-15 is a cytokine that activates NK [natural killer] cells and CD8-positive T cells. Therefore, this dual activation of innate and adaptive immunity is suggesting that we should use this component in various tumor types. The combination here with pembrolizumab is trying to overcome primary or secondary resistance. Currently, we are seeing activity in different situations, including primary and secondary resistance. This is clearly suggesting that this compound has a promising future in monotherapy or in combination in different indications.

There is a phase 2 [trial] that is currently being prepared, which would be the AURELIO-04 study using SOT101, the IL-15 superagonist, in combination with pembrolizumab in different tumor types, including non–small cell lung cancer, colorectal cancer, cutaneous squamous cell carcinoma, hepatocellular carcinoma, prostate cancer, and ovarian cancer.

Reference

Champiat S, Marabelle A, Galvao V, et al. SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: interim safety and efficacy results from the AURELIO-03 dose escalation trial. Presented at the 2022 American Association for Cancer Research Annual Meeting. New Orleans, LA. April 8-13, 2022.

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.